Has Frank Floca received payments from drug or device companies?

Yes. Drug and device makers reported $37,651 in general payments to Frank Floca across 382 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Frank Floca did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Frank Floca come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Frank Floca

Psychiatry · Austin, TXNPI 1962443382

Payments from drug & device makers

$37,651in general payments, 2019–2025

Across 382 payments — averaging $98.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Otsuka America Pharmaceutical, Inc.$29K
Alkermes, Inc.$2K
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
Teva Pharmaceuticals USA, Inc.$1K
Neurocrine Biosciences, Inc.$899
Avanir Pharmaceuticals, Inc.$360
plus $2K from 15 others

What the payments were for

Speaking & faculty fees$24,40065%
Travel & lodging$2,6387%
Food & beverage$10,53428%
Education$800%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Otsuka America Pharmaceutical, Inc.	102	$29,386
Alkermes, Inc.	82	$2,362
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	42	$1,444
Teva Pharmaceuticals USA, Inc.	60	$1,140
Neurocrine Biosciences, Inc.	17	$899
Avanir Pharmaceuticals, Inc.	6	$360
Vanda Pharmaceuticals Inc.	14	$302
Johnson & Johnson	15	$297
Acadia Pharmaceuticals Inc	6	$292
Lundbeck LLC	12	$225
E.r. Squibb & Sons, L.L.C.	6	$210
AbbVie(2 entities)	5	$207
Janssen Scientific Affairs, LLC	1	$120
Takeda Pharmaceuticals U.S.A., Inc.	1	$87
Indivior Inc.	3	$65
Supernus Pharmaceuticals, Inc.	3	$58
Boehringer Ingelheim	1	$58
Corium, LLC	3	$55
Otsuka Pharmaceutical Development & Commercialization, Inc.	1	$37
Alpha Cognition USA, Inc.	1	$36
Sun Pharmaceutical Industries Inc.	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$37,651 in reported general payments places this provider in the 90th percentile of 2,238 psychiatry providers in Texas.

See all psychiatry providers in Texas →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Invega SustennaPaliperidone Palmitate	32	$95,062
Risperdal ConstaRisperidone Microspheres	22	$42,873
Abilify MaintenaAripiprazole	13	$35,873
Oxcarbazepine	148	$13,443
AbrysvoRsv Vacc, Pref A And Pref B/Pf	38	$11,417
Naltrexone Hcl	30	$9,242
Rivastigmine	36	$8,690
NamzaricMemantine Hcl/Donepezil Hcl	12	$7,675
Memantine Hcl	138	$6,352
Clozapine	48	$5,561
Lisdexamfetamine Dimesylate	19	$4,827
Focalin XrDexmethylphenidate Hcl	18	$4,539
Dexmethylphenidate Hcl ErDexmethylphenidate Hcl	28	$4,470
ShingrixVaricella-Zoster Ge/As01b/Pf	19	$3,971
BelsomraSuvorexant	14	$3,879

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Johnson & JohnsonInvega Sustenna, Risperdal Consta	$297	$137,93654 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena	$29,386	$35,87313 claims
AbbVieNamzaric	$207	$7,67512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,238 psychiatry providers in Texas.

Other psychiatry in Austin

David BrownAustin$15.8M
Divyansu PatelAustin$2.8M
Donald GarciaAustin$2.8M
Arvinder Pal WaliaAustin$2.5M
Charles SweetAustin$520K
Charles NemeroffAustin$429K
Scott BartleyDallas$42.7M
Rajinder ShiwachDesoto$15.4M
Darin OkudaDallas$14.7M
Jason MensahBeaumont$10.3M

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →